PriceTargets.com logo

West Pharmaceutical Services - WST Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $313.00
  • Forecasted Upside: -8.92%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$343.67 As of 06/2/2023 01:00 AM ET
▲ +2.14 (0.63%)

This chart shows the closing price for WST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New West Pharmaceutical Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WST

Analyst Price Target is $313.00
▼ -8.92% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $313.00, with a high forecast of $400.00 and a low forecast of $250.00. The average price target represents a -8.92% upside from the last price of $343.67.

This chart shows the closing price for WST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in West Pharmaceutical Services. This rating has held steady since December 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2023StephensUpgradeEqual Weight ➝ Overweight$330.00 ➝ $400.00Low
2/22/2023Deutsche Bank AktiengesellschaftBoost Target$250.00 ➝ $290.00Low
2/17/2023KeyCorpBoost TargetOverweight$315.00 ➝ $375.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$250.00Low
12/2/2022KeyCorpLower TargetOverweight$350.00 ➝ $315.00Low
11/30/2022UBS GroupInitiated CoverageNeutral$250.00Low
10/28/2022Bank of AmericaDowngradeBuy ➝ Neutral$385.00 ➝ $250.00Low
10/28/2022KeyCorpLower TargetOverweight$400.00 ➝ $350.00Low
2/22/2022William BlairReiterated RatingOutperformHigh
7/30/2021KeyCorpBoost TargetOverweight$350.00 ➝ $475.00High
11/9/2020KeyCorpInitiated CoverageOverweight$350.00High
10/13/2020StephensInitiated CoverageEqual Weight$300.00High
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$280.00Low
4/24/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$145.00 ➝ $200.00High
12/12/2019Bank of AmericaDowngradeNeutral ➝ Underperform$135.00Medium
7/26/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
5/1/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$122.00Medium
4/23/2019William BlairInitiated CoverageOutperform ➝ Outperform$112.16Medium
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 8 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 14 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 15 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 19 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 19 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 19 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
Read More

Today's Range

Now: $343.67
Low: $339.99
High: $343.93

50 Day Range

MA: $353.40
Low: $334.30
High: $371.97

52 Week Range

Now: $343.67
Low: $206.19
High: $376.72

Volume

385,890 shs

Average Volume

526,322 shs

Market Capitalization

$25.51 billion

P/E Ratio

47.21

Dividend Yield

0.23%

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of West Pharmaceutical Services?

The following equities research analysts have issued reports on West Pharmaceutical Services in the last year: Bank of America Co., Deutsche Bank Aktiengesellschaft, KeyCorp, Stephens, StockNews.com, and UBS Group AG.
View the latest analyst ratings for WST.

What is the current price target for West Pharmaceutical Services?

5 Wall Street analysts have set twelve-month price targets for West Pharmaceutical Services in the last year. Their average twelve-month price target is $313.00, suggesting a possible downside of 8.9%. Stephens has the highest price target set, predicting WST will reach $400.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $250.00 for West Pharmaceutical Services in the next year.
View the latest price targets for WST.

What is the current consensus analyst rating for West Pharmaceutical Services?

West Pharmaceutical Services currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in WST, but not buy more shares or sell existing shares.
View the latest ratings for WST.

What other companies compete with West Pharmaceutical Services?

Other companies that are similar to West Pharmaceutical Services include Baxter International, ResMed, Insulet, Penumbra and Teleflex. Learn More about companies similar to West Pharmaceutical Services.

How do I contact West Pharmaceutical Services' investor relations team?

West Pharmaceutical Services' physical mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier's listed phone number is (610) 594-2900 and its investor relations email address is [email protected]. The official website for West Pharmaceutical Services is www.westpharma.com. Learn More about contacing West Pharmaceutical Services investor relations.